United States · FDA National Drug Code directory

LYBALVI

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
65757-654_44ae69cc-b9a6-4658-90fa-1dbef1e97eb4
Product NDC
65757-654
Form
TABLET, FILM COATED
Composition / generic term
olanzapine and samidorphan L-malate
Labeler
Alkermes, Inc.
Marketing category
NDA
Marketing start / end (source format)
20210920
Source listing expiry
20271231

Source-listed ingredients

  • OLANZAPINE — 20 mg/1
  • SAMIDORPHAN L-MALATE — 10 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 1 BOTTLE in 1 CARTON (65757-654-41) / 7 TABLET, FILM COATED in 1 BOTTLE · 65757-654-41
  • 1 BOTTLE in 1 CARTON (65757-654-42) / 30 TABLET, FILM COATED in 1 BOTTLE · 65757-654-42

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →